CAS: 1910-68-5; 2-(1-Methyl-2-Oxoindolin-3-Ylidene)Hydrazine-1-Carbothioamide

该化合物是一种主要因其抗病毒特性而得到承认的合成化合物,特别是针对某些病毒菌株的合成化合物,它属于硫诺衍生物类别,其特点是其独特的硫诺环结构,有助于其生物活动.梅西斯区通常用于研究环境,并研究其在病毒学和免疫学中的潜在应用.该化合物已知在水中表现出中等溶解性,并往往以各种溶剂制成,供实验室使用.其行动机制涉及干扰病毒复制过程,使其成为发展抗病毒疗法的兴趣对象.然而,由于它的具体应用和潜在副作用,其使用一般限于受控制的环境.与许多化学物质一样,在与梅西斯区合作减少与接触有关的任何健康风险时,适当的处理和安全防范是不可或缺的.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

1-methyl-1H-indole-2,3-dione thiosemicarbazide hydroxyimino-N-phenylacetamide indole-2,3-dione

合成工艺路线路线简述

    📜2-碘苯胺置于盐酸,甲基锂,溶剂黄146,1,8-二氮杂双环[5.4.0]十一碳-7-烯,Bis(Dibenzylideneacetone)-Palladium(0),Tri Tert-Butylphosphoniumtetrafluoroborate体系中,用 四氢呋喃,水 用作溶剂,化学反应 43.67H,反应生成美替沙腙
    参考文献:钯催化双羰基化方法从 2-碘苯胺制备靛红
    标题:钯催化双羰基化方法从 2-碘苯胺制备靛红
    摘要:已开发出合成靛红的高产程序.用接近化学计量的 Co 对 2-碘苯胺进行连续 Pd 催化双羰基化,然后进行酸促进环化,很容易得到一系列靛红.发现 2-碘苯胺以非常好到极好的收率转化为靛红,具有非常好的官能团耐受性.该协议证明适用于靛红的 13C 同位素标记,并扩展到 13C 同位素标记的抗病毒药物美替沙宗和实验性抗精神分裂症药物 Ml137 的合成.
    Doi:10.1002/ejoc.201600143

    海关参考信息

    专利信息


    专利号:US-2016185745-A1
    优先权日:2013-08-07
    标题:Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof
    发明人:SIEGEL DIONICIO; CHIN MATTHEW; ELIASEN ANDERS; AXELROD ABRAM
    权利人:UNIV TEXAS
    摘要:The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof.

    专利号:US-11649285-B2
    优先权日:2016-08-03
    标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
    发明人:KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
    权利人:BIO TECHNE CORP
    摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

    专利号:US-9522932-B2
    优先权日:2004-03-04
    标 题 :Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
    发明人:HERDEWIJN PIET; PANNECOUQUE CHRISTOPHE; WU TONGFEI; DE CLERCQ ERIK
    权利人:LEUVEN K U RES & DEV
    摘要:The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.

    专利号:US-10370455-B2
    优先权日:2014-12-05
    标题 :Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists
    发明人:MOLLOY MICHAEL; GUO YALIN; ROTHSTEIN JAY; ROSENZWEIG MICHAEL
    权利人:IMMUNEXT INC
    摘要:The receptor for VISTA is identified (VSIG8) as well as the use of this receptor in the identification or synthesis of agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG8 and/or VISTA and/or the VSIG8/VISTA binding interaction. These antagonists may be used to suppress VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

    专利号:US-10065924-B2
    优先权日:2014-07-22
    标 题 :Preparation and biological evaluation of viridicatumtoxin analogs
    发明人:NICOLAOU KYRIACOS C; HALE CHRISTOPHER R H; NILEWSKI CHRISTIAN; IOANNIDOU HERAKLIDIA; EL MARROUNI ABDELLATIF
    权利人:UNIV RICE WILLIAM M
    摘要:In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.

    专利号:WO-2009056955-A1
    优先权日:2007-10-30
    标题 :Amine-bearing phospholipids (abps), their synthesis and use
    发明人:ZUMBUEHL ANDREAS
    权利人:UNIV BASEL; ZUMBUEHL ANDREAS
    摘要:Disclosed herein are amine-bearing phospholipids (ABP). The ABPs display many properties and functionalities of naturally occurring phospholipids, but also new properties and functionalities, such as the ability to polymerize while maintaining structural integrity, that may supplement or expand the functionalities of naturally occurring phospholipids.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Teitz Y, Ronen D, Vansover A, Stematsky T, Riggs JL. Inhibition of human immunodeficiency virus by N-methylisatin-beta 4':4'-diethylthiosemicarbazone and N-allylisatin-beta-4':4'-diallythiosemicarbazone. Antiviral Res. 1994 Aug;24(4):305-14.
    3: Ronen D, Sherman L, Bar-Nun S, Teitz Y. N-methylisatin-beta-4',4'-diethylthiosemicarbazone, an inhibitor of Moloney leukemia virus protein production: characterization and in vitro translation of viral mRNA. Antimicrob Agents Chemother. 1987 Nov;31(11):1798-802.
    4: BAUER DJ, STVINCENT L, KEMPE CH, DOWNIE AW. PROPHYLACTIC TREATMENT OF SMALL POX CONTACTS WITH N-METHYLISATIN BETA-THIOSEMICARBAZONE (COMPOUND 33T57, MARBORAN). Lancet. 1963 Sep 7;2(7306):494-6. Review. Ukrainian. Review. Review.

    合成参考文献


    摘要:U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals., NX#02255
    摘要:Arzneimittel-Forschung. Drug Research., 22(1704), 1972 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知